National Lung Cancer Audit 2014

<h1>Making clinical audit data transparent</H1>

In his transparency and open data letter to Cabinet Ministers on 7 July 2011, the Prime Minister restated the commitment to make clinical audit data available from the national audits within the National Clinical Audit and Patient Outcomes Programme. The National Lung Cancer Audit (NLCA) was identified as the pilot for this data release.

The data was released in an open and standardised format for the first time in December 2011, and each year onward, data from the National Lung Cancer Audit will be made available in CSV format. The data are also being made available on the data.gov website.

Covering all Strategic Clinical Networks and NHS Trusts in England, the data from the audit includes information about data completeness, audit process and outcome measures. The data will be available in a pdf format with the National Lung Cancer Audit 2014 annual report.

<b>♯ What information is being made available? ♯</b>

<UL><LI>☼ Measures about the process of care given to patients </LI>

<LI>☼ Information about care outcomes and treatment.</LI>

<LI>☼ The data also provides Audit participation by Trust and data completeness for the key fields. </LI></UL>

This data does not list data about individual patients nor does it contain any patient identifiable data.

<B>♯ Using and interpreting the data ♯</b>

Data from the National Lung Cancer Audit requires careful interpretation, and the information should not be looked at in isolation when assessing standards of care.

Data is analysed either by cancer network or by place first seen in secondary care for the calendar year 2013 (except where noted). As a result, some trusts that only provide some specialist treatments for patients and do not routinely supply diagnostic data are not properly represented in these data. This is because all the analyses of the NLCA to date have been carried out by 'place first seen' and clinical networks. The ‘place first seen' most closely represents the Clinical Multi-Disciplinary Team (MDT) which makes the first treatment decisions (in partnership with representatives from the specialist centres who sit on these peripheral MDTs).

We largely know the population base for these MDTs and that number provides the ‘denominator' for the outcome measures. It is much more difficult to define a population denominator for specialist centres and the treatment they provide is usually only one part of a complex care pathway. So taking the raw data at face value gives a very distorted picture both of their activity and performance.

<B>♯ Accessing the data ♯</B>

The data are being made available on the data.gov website. Each year three files of data from the National Lung Cancer Audit will be made available in CSV format. Trusts and Networks are identified by name and their national code.

<B>♯ What does the data cover? ♯</B>

The data measure levels of completeness for data submitted to the NLCA and measures of performance in the audit at trust level for key performance measures for assessing standards of care for lung cancer in secondary care. Details of these standards can be found in appendix 2 of the NLCA report.

<B>♯ Are all Trusts included? ♯</B>

All Trusts in England that manage patients diagnosed with lung cancer (excluding mesothelioma) are included. The audit also covers Wales.

<B>♯ What period does the data cover? ♯</B>

This data were extracted from the NLCA database in July 2014 and covers patients first seen in the calendar year 2013 (except where noted).

<h1>构建临床审计数据透明度</H1>在其于2011年7月7日致内阁部长的透明度和开放数据信函中，首相重申了从国家临床审计和患者结果计划中的国家审计中提供临床审计数据的承诺。国家肺癌审计（NLCA）被选为这一数据发布的试点项目。该数据首次以开放和标准化的格式于2011年12月发布，此后，国家肺癌审计的数据每年将以CSV格式提供。数据亦可在data.gov网站上获得。涵盖英格兰所有战略临床网络和NHS信托机构，审计数据包括关于数据完整性、审计流程和结果指标的信息。这些数据将以PDF格式与国家肺癌审计2014年年度报告一同提供。<b>♯ 信息公开内容 ♯</b><ul><li>☼ 关于对病人提供护理过程的各种指标</li><li>☼ 关于护理结果和治疗的信息</li><li>☼ 数据还提供了由信托机构和关键字段的数据完整性所参与的审计。</li></ul>该数据不包含关于个别病人的信息，也不包含任何可识别病人的数据。<b>♯ 数据的使用与解读 ♯</b>国家肺癌审计的数据需要谨慎解读，在评估护理标准时，不应孤立地看待这些信息。数据由癌症网络或2013年日历年首次在二级护理中就诊的地点进行分析（除非另有说明）。因此，一些仅提供某些专科治疗且不常规提供诊断数据的信托机构在这些数据中未能得到充分体现。这是因为迄今为止，所有NLCA的分析都是基于“首次就诊地点”和临床网络进行的。“首次就诊地点”最接近代表作出首次治疗决定的临床多学科团队（MDT）（与坐在这些外围MDT上的专科中心代表合作）。我们大致了解这些MDT的人口基数，这个数字为结果指标提供了‘分母’。为专科中心和它们提供的服务定义人口分母要困难得多，它们提供的服务通常是复杂护理途径的一部分。因此，仅从原始数据中获取信息会对其活动和表现造成严重的扭曲。<b>♯ 数据访问 ♯</b>数据可在data.gov网站上获得。每年将提供三个来自国家肺癌审计的数据文件，以CSV格式提供。信托机构和网络均以名称和国家代码标识。<b>♯ 数据覆盖范围 ♯</b>数据衡量了提交给NLCA的数据的完整性水平，以及评估二级护理中肺癌护理标准的信托层面的关键绩效指标的绩效衡量。《NLCA报告》附录2中可以找到这些标准的详细情况。<b>♯ 是否所有信托机构均包括在内？ ♯</b>包括所有管理被诊断为肺癌（不包括石棉肺）的病人的英格兰信托机构（威尔士也被审计）。<b>♯ 数据覆盖的时期是什么时候？ ♯</b>这些数据于2014年7月从NLCA数据库中提取，涵盖了2013年日历年首次就诊的病人（除非另有说明）。